Wasawas, Nilda T.
HRN: 13-38-22 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/22/2023
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
03/22/2023
03/29/2023
IV
2.25g
Q 6H
Sepsis Sec To DM Foot, L And CAP-MR
Waiting Final Action
Indication: Empiric Type of Infection: PneumoniaBone & JointSkin & Soft TissueMultiple Infections (tick All Sites) Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes